The answer depends on your health profile, weight loss goals, and a thorough discussion with your healthcare provider
It is a tripeptide composed of three amino acids: cysteine, glycine, and glutamine
Research Citations Christensen, M., Knop, F
Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes

Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program, Diabetes Care (2022) What causes obesity & overweight?, Eunice Kennedy Shriver National Institute of Child Health and Human Development (2021) Compounding and the FDA: Questions and Answers, Food and Drug Administration (2024) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes, Reviews in Endocrine and Metabolic Disorders (2022) FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Thinking of using a compounding pharmacy